Adverse Effects Impact Treatment Selection for VEGF-Targeted Oral TKIs in Metastatic RCC
Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Source: pharmacytimes.com
Page 20 - Practice Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Practice Guidelines Today - Breaking & Trending Today
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb...
Source: prnewswire.com
New BiTE Agents Provide Effective Options for Treatment of Relapsed/Refractory Multiple Myeloma
Seven new agents have received FDA approval since October 2022.
Source: pharmacytimes.com
Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN Study
/PRNewswire/ -- New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line...
Source: prnewswire.com
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...
Source: prnewswire.com